Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:BTMDNASDAQ:ICCCNASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$9.11-2.7%$9.78$7.08▼$20.60$187.07M1.3872,691 shs115,140 shsBTMDbiote$3.30-0.3%$3.92$3.04▼$8.44$180.54M1.17186,781 shs108,305 shsICCCImmuCell$5.50+0.2%$5.08$3.34▼$5.82$49.41M0.3921,363 shs4,087 shsOCGNOcugen$0.68+4.0%$0.64$0.52▼$2.06$198.39M3.784.80 million shs3.49 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-2.67%+0.89%+5.27%-18.37%-50.33%BTMDbiote-0.30%-1.49%-18.92%-41.49%-40.22%ICCCImmuCell+0.18%+8.48%+14.35%+4.56%+8.91%OCGNOcugen+4.01%+1.46%+31.59%-4.31%-52.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.2486 of 5 stars1.02.00.00.02.20.00.0BTMDbiote3.2639 of 5 stars3.52.00.00.03.63.31.3ICCCImmuCell0.1006 of 5 stars0.03.00.00.00.60.00.0OCGNOcugen1.2928 of 5 stars3.51.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-23.16% DownsideBTMDbiote 3.00Buy$8.00142.42% UpsideICCCImmuCell 0.00N/AN/AN/AOCGNOcugen 3.00Buy$6.33832.20% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, OCGN, AMRN, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/13/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/13/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.001/23/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.82N/AN/A$1.35 per share6.75BTMDbiote$197.19M0.92$0.34 per share9.60($0.58) per share-5.69ICCCImmuCell$26.49M1.86N/AN/A$3.23 per share1.70OCGNOcugen$4.06M48.93N/AN/A$0.16 per share4.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)BTMDbiote$3.32M$0.1812.696.11N/A5.20%-32.41%22.26%5/6/2025 (Estimated)ICCCImmuCell-$5.78M-$0.29N/A∞N/A-15.99%-15.32%-8.81%5/14/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%5/13/2025 (Estimated)Latest ICCC, OCGN, AMRN, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/AN/AN/A5/6/2025Q1 2025BTMDbiote$0.06N/AN/AN/A$47.25 millionN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million2/25/2025Q4 2024ICCCImmuCellN/A$0.06N/A$0.06N/A$7.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11BTMDbioteN/A1.501.16ICCCImmuCell0.363.111.44OCGNOcugen0.042.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BTMDbiote21.68%ICCCImmuCell13.47%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%BTMDbiote24.00%ICCCImmuCell6.60%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.53 million402.62 millionOptionableBTMDbiote19454.71 million46.78 millionNot OptionableICCCImmuCell708.98 million8.32 millionNot OptionableOCGNOcugen80292.01 million278.82 millionOptionableICCC, OCGN, AMRN, and BTMD HeadlinesRecent News About These CompaniesIs Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?April 17 at 5:47 AM | msn.comOcugen CEO to Present at Prestigious Cell & Gene Meeting on the MediterraneanApril 10, 2025 | msn.comOcugen management to meet with MaximApril 9, 2025 | markets.businessinsider.comOcugen to Present at the 2025 Cell & Gene Meeting on the MedApril 8, 2025 | globenewswire.comOcugen (NASDAQ:OCGN) vs. Coherus BioSciences (NASDAQ:CHRS) Head to Head SurveyApril 8, 2025 | americanbankingnews.comStargardt Disease Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Acucela, Astellas Pharma, Alkeus PharmaApril 7, 2025 | theglobeandmail.comChardan Capital Forecasts Ocugen FY2025 EarningsMarch 28, 2025 | marketbeat.comOcugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200March 21, 2025 | ophthalmologytimes.comOcugen receives DSMB approval to continue dosing in Phase I trial of OCU200March 19, 2025 | clinicaltrialsarena.comOcugen Advances OCU200 Clinical Trial Amid Promising Safety ResultsMarch 19, 2025 | msn.comOcugen says DSMB approves dosing Cohort 2 in OCU200 clinical trialMarch 18, 2025 | markets.businessinsider.comData and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular EdemaMarch 18, 2025 | globenewswire.comOcugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your BehalfMarch 6, 2025 | financialpost.comOcugen, Inc. (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comOcugen reports Q4 EPS (5c), consensus (5c)March 6, 2025 | markets.businessinsider.comOcugen (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comOcugen Reports Progress in Gene Therapy TrialsMarch 5, 2025 | tipranks.comOcugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400March 5, 2025 | quiverquant.comOcugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial ResultsMarch 5, 2025 | globenewswire.comNoble Financial Sticks to Its Buy Rating for Ocugen (OCGN)March 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, OCGN, AMRN, and BTMD Company DescriptionsAmarin NASDAQ:AMRN$9.11 -0.25 (-2.67%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.38 +0.27 (+2.96%) As of 04/17/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.biote NASDAQ:BTMD$3.30 -0.01 (-0.30%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.40 +0.10 (+3.03%) As of 04/17/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.ImmuCell NASDAQ:ICCC$5.50 +0.01 (+0.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Ocugen NASDAQ:OCGN$0.68 +0.03 (+4.01%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.67 -0.01 (-0.79%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
